WO2001016168A3 - Induction of programmed cell death by n5 gene - Google Patents

Induction of programmed cell death by n5 gene Download PDF

Info

Publication number
WO2001016168A3
WO2001016168A3 PCT/US2000/024075 US0024075W WO0116168A3 WO 2001016168 A3 WO2001016168 A3 WO 2001016168A3 US 0024075 W US0024075 W US 0024075W WO 0116168 A3 WO0116168 A3 WO 0116168A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
induction
cell death
programmed cell
cancer
Prior art date
Application number
PCT/US2000/024075
Other languages
French (fr)
Other versions
WO2001016168A2 (en
WO2001016168A9 (en
Inventor
David Goodrich
Jaleh Doostzadeh
Shenmin Yin
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Priority to EP00959759A priority Critical patent/EP1208114A2/en
Priority to CA002382952A priority patent/CA2382952A1/en
Priority to AU71024/00A priority patent/AU7102400A/en
Publication of WO2001016168A2 publication Critical patent/WO2001016168A2/en
Publication of WO2001016168A3 publication Critical patent/WO2001016168A3/en
Publication of WO2001016168A9 publication Critical patent/WO2001016168A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns methods and compositions for treating cancer in a subject. These methods and compositions utilize the activities associated with the N5 gene product, p84N5. p84N5 contains a functional death domain, can interact with the retinoblastoma gene product and is normally localized to the nucleus of cells. Increasing the activity level of p84N5 in cancer cells is beneficial for the treatment of cancer.
PCT/US2000/024075 1999-08-31 2000-08-31 Induction of programmed cell death by n5 gene WO2001016168A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00959759A EP1208114A2 (en) 1999-08-31 2000-08-31 Induction of programmed cell death by n5 gene
CA002382952A CA2382952A1 (en) 1999-08-31 2000-08-31 Induction of programmed cell death by n5 gene
AU71024/00A AU7102400A (en) 1999-08-31 2000-08-31 Induction of programmed cell death by n5 gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15168799P 1999-08-31 1999-08-31
US60/151,687 1999-08-31

Publications (3)

Publication Number Publication Date
WO2001016168A2 WO2001016168A2 (en) 2001-03-08
WO2001016168A3 true WO2001016168A3 (en) 2001-06-14
WO2001016168A9 WO2001016168A9 (en) 2002-09-12

Family

ID=22539841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024075 WO2001016168A2 (en) 1999-08-31 2000-08-31 Induction of programmed cell death by n5 gene

Country Status (4)

Country Link
EP (1) EP1208114A2 (en)
AU (1) AU7102400A (en)
CA (1) CA2382952A1 (en)
WO (1) WO2001016168A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015071A1 (en) * 2007-07-23 2009-01-29 Dharmacon, Inc. Screening of micro-rna cluster inhibitor pools

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031603A2 (en) * 1995-04-03 1996-10-10 The Regents Of The University Of Michigan Methods and compositions for regulating fadd

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031603A2 (en) * 1995-04-03 1996-10-10 The Regents Of The University Of Michigan Methods and compositions for regulating fadd

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOOSTZADEH-CIZERON J ET AL: "The nuclear death domain protein p84N5 activates a G(2)/M cell cycle checkpoint prior to the onset of apoptosis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 2, 12 January 2001 (2001-01-12), pages 1127 - 1132, XP000989608 *
DOOSTZADEH-CIZERON JALEH ET AL: "Apoptosis induced by the nuclear death domain protein p84N5 is inhibited by association with Rb protein.", MOLECULAR BIOLOGY OF THE CELL, vol. 10, no. 10, October 1999 (1999-10-01), pages 3251 - 3261, XP002162559, ISSN: 1059-1524 *
DURFEE TIM ET AL: "The amino-terminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that co-localizes to centers for RNA processing.", JOURNAL OF CELL BIOLOGY, vol. 127, no. 3, 1994, pages 609 - 622, XP000987005, ISSN: 0021-9525 *
FEINSTEIN, ELENA ET AL: "The death domain: a module shared by proteins with diverse cellular functions", TRENDS BIOCHEM. SCI., vol. 20, no. 9, 1995, pages 342 - 344, XP004222306 *
YIN SHENMIN ET AL: "Adenovirus-mediated N5 gene transfer inhibits tumor cell proliferation by induction of apoptosis.", CANCER GENE THERAPY, vol. 7, no. 7, July 2000 (2000-07-01), pages 985 - 990, XP000986995, ISSN: 0929-1903 *

Also Published As

Publication number Publication date
EP1208114A2 (en) 2002-05-29
WO2001016168A2 (en) 2001-03-08
WO2001016168A9 (en) 2002-09-12
CA2382952A1 (en) 2001-03-08
AU7102400A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
WO2000071703A3 (en) Inhibition of histone deacetylase
WO2005030121A3 (en) Compounds, compositions and methods
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
GB9903762D0 (en) Organic compounds
HK1038590A1 (en) Methods and means to modulate programmed cell death in eukaryotic cells
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
IL192762A0 (en) Method for identifying cell differentiation factors
GB2437027A (en) Differentiation of human embryonic stem cells and cardiomyocytes and cardiomyocyte progenitors derived therefrom
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2001014584A3 (en) Methods of identifying anti-viral agents
WO2006021002A3 (en) Compounds useful for inhibiting chk1
WO2001021771A3 (en) Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
WO2004101889A8 (en) Use of hemicellulase composition in mechanical pulp production
EP1189918A4 (en) Antisense modulation of integrin beta 3 expression
IL124015A0 (en) Pharmaceutical compositions comprising a protein
WO2001016168A3 (en) Induction of programmed cell death by n5 gene
MXPA06007269A (en) Compositions and methods for combined therapy of disease.
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
EP1250347A4 (en) Antisense modulation of akt-3 expression
De Leo et al. Iron modulation of LPS-induced manganese superoxide dismutase gene expression in rat tissues
WO2004003152A3 (en) Sos1 inhibitors
EP1220866A4 (en) Antisense modulation of bcl-6 expression
EP0967278A3 (en) Flowering regulating gene and its use
AU3655400A (en) Utilization of porphyrin derivatives in aquaria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2382952

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000959759

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000959759

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-166, DESCRIPTION, REPLACED BY NEW PAGES 1-162; PAGES 167-170, CLAIMS, REPLACED BY NEW PAGES163-166; PAGES 1-5, SEQUENCE LISTING, REPLACED BY NEW PAGES 1-5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000959759

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP